Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting
- Conditions
- Mucopolysaccharidosis Type I (MPS I)Pompe Disease
- First Posted Date
- 2021-10-11
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT05073783
- Locations
- 🇮🇹
Investigational Site Italy, Italy, Italy
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
- Conditions
- Adenocarcinoma GastricGastrooesophageal Cancer
- Interventions
- Drug: Tusamitamab ravtansine (SAR408701)
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT05071053
- Locations
- 🇯🇵
Investigational Site Number : 3920004, Matsuyama-shi, Ehime, Japan
🇯🇵Investigational Site Number : 3920002, Kashiwa-shi, Chiba, Japan
🇹🇷Investigational Site Number : 7920003, Ankara, Turkey
A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
- Conditions
- Asthma
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 105
- Registration Number
- NCT05070663
- Locations
- 🇫🇷
Investigational site France, France, France
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 59
- Registration Number
- NCT05061420
- Locations
- 🇺🇸
City of Hope- Site Number : 8400007, Duarte, California, United States
🇺🇸University of Colorado- Site Number : 8400004, Aurora, Colorado, United States
🇺🇸University of Michigan- Site Number : 8400008, Ann Arbor, Michigan, United States
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT05049122
- Locations
- 🇯🇵
Investigational site JAPAN, Japan, Japan
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
- Conditions
- Hemophilia A
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT05042440
- Locations
- 🇧🇬
Investigational Site Number :1000001, Sofia, Bulgaria
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: SAR441344 IVDrug: Placebo IVDrug: SAR441344 SCDrug: Placebo SC
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 116
- Registration Number
- NCT05039840
- Locations
- 🇺🇸
Columbia University Medical Center - New York- Site Number : 8400009, New York, New York, United States
🇺🇸Accel Research Sites Network - Birmingham- Site Number : 8400003, Birmingham, Alabama, United States
🇺🇸AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler- Site Number : 8400026, Chandler, Arizona, United States
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 124
- Registration Number
- NCT05018806
- Locations
- 🇺🇸
Integrative Skin Care of MS/SKYCRNG Site Number : 8400011, Ridgeland, Mississippi, United States
🇵🇱Investigational Site Number : 6160005, Gdansk, Pomorskie, Poland
🇵🇱Investigational Site Number : 6160002, Lodz, Poland
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
- Conditions
- Breast CancerNeoplasm MalignantLung Neoplasm MalignantGastric CancerNeoplasm
- Interventions
- Drug: SAR443216 IVDrug: SAR443216 SC
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT05013554
- Locations
- 🇺🇸
~University of Texas - MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇧🇪Investigational Site Number : 0560002, Gent, Belgium
🇫🇷Investigational Site Number : 2500001, Pierre Benite, France
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine 300 U/ml
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 570
- Registration Number
- NCT05002933
- Locations
- 🇨🇳
Investigational Sites, China, China